Recent progress in tolerance induction through mixed chimerism

International Archives of Allergy and Immunology

Volumn 144, Issue 3, 2007, Pages 254-266

  Pree, Ines ^a   Pilat, Nina ^a   Wekerle, Thomas ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chimerism; Costimulation blockade; Tolerance; Transplantation

Indexed keywords

ABATACEPT; BUSULFAN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

BONE MARROW TRANSPLANTATION; CHIMERA; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MYELOABLATIVE CONDITIONING; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION;

ANIMALS; GRAFT REJECTION; HUMANS; MODELS, ANIMAL; ORGAN TRANSPLANTATION; SELF TOLERANCE; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE;

EID: 35348833592     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104740     Document Type: Review

References (121)

1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185.
2. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-2333.
3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transpl 2004;4:905-913.
4. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
5. Owen RD: Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400-401.
6. Starzl TE, Zinkernagel RM: Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001;1:233-239.
7. Billingham RE, Brent L, Medawar PB: 'Actively acquired tolerance' of foreign cells. Nature 1953;172:603-606.
8. Main JM, Prehn RT: Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 1955;1023-1028.
9. Sykes M, Sheard MA, Sachs DH: Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988;168:2391-2396.
10. Singer A, Hathcock KS, Hodes RJ: Self recognition in allogeneic radiation chimeras: a radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells. J Exp Med 1981;153:1286-1301.
11. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
12. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH: Characterization of mixed allogeneic chimeras: immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 1985;162:231-244.
13. Guo Z, Wang J, Dong Y, Adams AB, Shirasugi N, Kim O, Hart J, Newton-West M, Pearson TC, Larsen CP, et al: Long-term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion. Am J Transplant 2003;3:1091-1098.
14. Tomita Y, Khan A, Sykes M: Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantion in mice conditioned with a non-myeloablative regimen. J Immunol 1994;153:1087-1098.
15. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M: Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a non-myeloablative conditioning regimen. Transplantation 1998;66:96-102.
16. Zinkernagel RM, Callahan GN, Althage A, Cooper S, Klein PA, Klein J: On the thymus in the differentiation of 'H-2 self-recognition' by T cells: evidence for dual recognition? J Exp Med 1978;147:882-896.
17. Iwai T, Tomita Y, Zhang QW, Shimizu I, Nomoto K, Yasui H: Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance. Transpl Int 2005;17:795-803.
18. Ashton-Chess J, Brouard S, Soulillou J-P: Is clinical tolerance realistic in the next decade? Transpl Int 2006;19:539-548.
19. Tomita Y, Sachs DH, Sykes M: Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood 1994;83:939-948.
20. Cobbold SP, Martin G, Qin S, Waldmann H: Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986;323:164-165.
21. Sharabi Y, Sachs DH: Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989;169:493-502.
22. Wekerle T, Nikolic B, Pearson DA, Swenson KG, Sykes M: Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int 2002;15:248-253.
23. Tomita Y, Sachs DH, Khan A, Sykes M: Additional mAb injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 1996;61:469-477.
24. Huang CA, Fuchimoto Y, Scheier-Dolberg R, Murphy MC, Neville DM Jr, Sachs DH: Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000;105:173-181.
25. Sykes M, Szot GL, Swenson K, Pearson DA: Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997;3:783-787.
26. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
27. Wekerle T, Sayegh MH, Ito H, Hill J, Chandraker A, Pearson DA, Swenson KG, Zhao G, Sykes M: Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999;68:1348-1355.
28. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG, Zhao G, Sykes M: Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998;187:2037-2044.
29. Adams AB, Durham MM, Kean L, Shirasugi N, Ha J, Williams MA, Rees PA, Cheung MC, Mittelstaedt S, Bingaman AW, et al: Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001;167:1103-1111.
30. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR: Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001;98:467-474.
31. Williams MA, Trambley J, Ha J, Adams AB, Durham MM, Rees P, Cowan SR, Pearson TC, Larsen CP: Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000;165:6849-6857.
32. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794.
33. Sykes M, Ohdan H, Manilay JO, Wekerle T, Yang YG: Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Transpl Proc 1998;30:420.
34. Yang Y-G, deGoma E, Ohdan H, Bracy JL, Xu Y, Iacomini J, Thall AD, Sykes M: Tolerization of anti-Galα 1-3Gal natural antibody-forming B cells by induction of mixed chimerism. J Exp Med 1998;187:1335-1342.
35. Zhao Y, Ohdan H, Manilay JO, Sykes M: NK cell tolerance in mixed allogeneic chimeras. J Immunol 2003;170:5398-5405.
36. Ito H, Kurtz J, Shaffer J, Sykes M: CD4 T cellmediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001;166:2970-2981.
37. Quesenberry PJ, Zhong S, Wang H, Stewart M: Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice. Blood 2001;97:557-564.
38. Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, Greiner DL: Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000;95:2175-2182.
39. Seung E, Mordes JP, Rossini AA, Greiner DL: Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest 2003;112:795-808.
40. Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, Bergmeister H, Wrba F, Kurtz J, Kiss C, et al: The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003;101:2886-2893.
41. Durham MM, Bingaman AW, Adams AB, Ha J, Waitze S-Y, Pearson TC, Larsen CP: Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000;165:1-4.
42. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995;181:1869-1874.
43. Bigenzahn S, Blaha P, Koporc Z, Pree I, Selzer E, Bergmeister H, Wrba F, Heusser C, Wagner K, Muehlbacher F, et al: The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 2005;5:1237-1247.
44. Ito H, Takeuchi Y, Shaffer J, Sykes M: Local irradiation enhances congenic donor pluripotent hematopoietic stem cell engraftment similarly in irradiated and nonirradiated sites. Blood 2004;103:1949-1954.
45. Kean LS, Durham MM, Adams AB, Hsu LL, Perry JR, Dillehay D, Pearson TC, Waller EK, Larsen CP, Archer DR: A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002;99:1840-1849.
46. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000;6:464-469.
47. Kean LS, Hamby K, Koehn B, Lee E, Coley S, Stempora L, Adams AB, Heiss E, Pearson TC, Larsen CP: NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant 2006;6:292-304.
48. Blaha P, Bigenzahn S, Koporc Z, Sykes M, Muehlbacher F, Wekerle T: Short-term immunosuppression facilitates induction of mixed chimerism and tolerance after bone marrow transplantation without cytoreductive conditioning. Transplantation 2005;80:237-243.
49. Koporc Z, Bigenzahn S, Blaha P, Fariborz E, Selzer E, Sykes M, Muehlbacher F, Wekerle T: Induction of mixed chimerism through transplantation of CD45-congenic mobilized peripheral blood stem cells after nonmyeloablative irradiation. Biol Blood Marrow Transplant 2006;12:284-292.
50. Graca L, Daley S, Fairchild P, Cobbold S, Waldmann H: Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning. BMC Immunol 2006;7:9.
51. Westerhuis G, Maas WGE, Willemze R, Toes REM, Fibbe WE: Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 2005;106:2215-2220.
52. Taylor PA, Lees CJ, Wilson JM, Ehrhardt MJ, Campbell MT, Noelle RJ, Blazar BR: Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002;100:3400-3407.
53. Adams AB, Shirasugi N, Jones TR, Williams MA, Durham MM, Ha J, Dong Y, Guo Z, Newell KA, Pearson TC, et al: Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003;3:895-901.
54. Kirk AD, Blair PJ, Tadaki DK, Xu H, Harlan DM: The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci 2001;356:691-702.
55. Taylor PA, Friedman TM, Korngold R, Noelle RJ, Blazar BR: Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002;99:4601-4609.
56. Monk NJ, Hargreaves RE, Marsh JE, Farrar CA, Sacks SH, Millrain M, Simpson E, Dyson J, Jurcevic S: Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003;9:1275-1280.
57. + T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000;191:651-660.
58. + cells. Am J Transplant 2001;1:339-349.
59. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Rae Cho H, Aruffo A, Hollenbaugh D, Linsley PS, et al: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
60. Bluestone JA: CTLA-4Ig is finally making it: a personal perspective. Am J Transplant 2005;5:423-424.
61. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH: CTLA-4 regulates induction of anergy in vivo. Immunity 2001;14:145-155.
62. Finger EB, Bluestone JA: When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat Immunol 2002;3:1056-1057.
63. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, et al: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-1101.
64. Pree I, Bigenzahn S, Fuchs D, Koporc Z, Nierlich P, Winkler C, Brandacher G, Sykes M, Muehlbacher F, Langer F, et al: CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2,3- dioxygenase (IDO). Transplantation 2007;83:663-667.
65. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, et al: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999;5:1303-1307.
66. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Med 1999;5:1298-1302.
67. + T cells, precluding a role for sustained regulation. Eur J Immunol 2005;35:2679-2690.
68. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M: Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. Blood 2004;103:4336-4343.
69. Wekerle T, Kurtz J, Sayegh MH, Ito H, Wells AD, Bensinger S, Shaffer J, Turka LA, Sykes M: Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001;166:2311-2316.
70. Domenig C, Sanchez-Fueyo A, Kurtz J, Alexopoulos SP, Mariat C, Sykes M, Strom TB, Zheng XX: Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol 2005;175:51-60.
71. Bemelman F, Honey K, Adams E, Cobbold S, Waldmann H: Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. J Immunol 1998;160:2645-2648.
72. Kurtz J, Wekerle T, Sykes M: Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol 2004;25:518-523.
73. Fugier-Vivier IJ, Rezzoug F, Huang Y, Graul-Layman AJ, Schanie CL, Xu H, Chilton PM, Ildstad ST: Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med 2005;201:373-383.
74. Jacquet EG, Schanie CL, Fugier-Vivier I, Willer SS, Ildstad ST: Facilitating cells as a venue to establish mixed chimerism and tolerance. Pediatr Transplant 2003;7:348-357.
75. Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y: Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin. Exp Hematol 2006;34:802-808.
76. Hanash AM, Levy RB: Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005;105:1828-1836.
77. Steiner D, Brunicki N, Blazar BR, Bachar-Lustig E, Reisner Y: Tolerance induction by third-party 'off-the-shelf' CD4+CD25+ Treg cells. Exp Hematol 2006;34:66-71.
78. Adams AB, Pearson TC, Larsen CP: Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003;196:147-160.
79. Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R, Larsen CP: Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002;169:5387-5391.
80. Gleit ZL, Fuchimoto Y, Yamada K, Melendy E, Scheier-Dolberg R, Monajati L, Coburn RC, Neville DM Jr, Sachs DH, Huang CA: Variable relationship between chimerism and tolerance after hematopoietic cell transplantation without myelosuppressive conditioning. Transplantation 2002;74:1535-1544.
81. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem HP, Nash RA, McSweeney PA, Wagner JL: Stable mixed chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999;94:2523-2529.
82. Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T, Sykes M, Monroy R, Tanaka M, Sachs DH: Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys. Transplantation 1995;59:256-262.
83. Kawai T, Cosimi AB, Wee SL, Houser S, Andrews D, Sogawa H , Phelan J, Boskovic S, Nadazdin O, Abrahamian G, et al: Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002;73:1757-1764.
84. Kawai T, Sogawa H, Koulmanda M, Smith RN, O'Neil JJ, Wee SL, Boskovic S, Sykes M, Colvin RB, Sachs DH, et al: Long-term islet allograft function in the absence of chronic immunosuppression: a case report of a nonhuman primate previously made tolerant to a renal allograft from the same donor. Transplantation 2001;72:351-354.
85. Kawai T, Poncelet A, Sachs D, Mauiyyedi S, Boskovic S, Wee S, Ko D, Bartholomew A, Kimikawa M, Hong H, et al: Long-term outcome and alloantibody production in a nonmyeloablative regimen for induction of renal allograft tolerance. Transplantation 1999;68:1767-1775.
86. Kawai T, Wee SL, Bazin H, Latinne D, Phelan J, Boskovic S, Ko DS, Hong HZ, Mauiyyedi S, Nadazdin O, et al: Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in nonhuman primates. Tansplantation 2000;70:368-374.
87. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith R-N, Wee S-L, Andrews D, Nadazdin O, Koyama I, Sykes M, et al: CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004;4:1391-1398.
88. Kean LS, Gangappa S, Pearson TC, Larsen CP: Transplant tolerance in non-human primates: Progress, current challenges and unmet needs. Am J Transplant 2006;6:884-893.
89. Bühler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, Saidman SL, Sackstein R, McAffee S, Dey B, et al: Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and endstage renal disease. Transplantation 2002;74:1405-1409.
90. Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, et al: Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006;6:2121-2133.
91. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAffee S, Sackstein R, Saidman S, Colby C, Sykes M, Sachs DH, Cosimi AB: Combined histocompatible leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480-484.
92. Sidiropoulos PI, Boumpas DT: Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13:391-397.
93. Vincenti F: What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002;2:898-903.
94. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-727.
95. Pree I, Wekerle T: New approaches to prevent transplant rejection: co-stimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today Ther Strateg 2006;3:41-47.
96. Pluvinet R, Petriz J, Torras J, Herrero-Fresneda I, Cruzado JM, Grinyo JM, Aran JM: RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004;104:3642-3646.
97. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, et al: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-4398.
98. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J: 'Superhumanized' antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol 2002;169:1119-1125.
99. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114-1123.
100. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915.
101. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, et al: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443-453.
102. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, et al: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-781.
103. Kean LS, Adams AB, Strobert E, Hendrix R, Gangappa S, Jones TR, Shirasugi N, Rigby MR, Hamby K, Jiang J, et al: Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant 2007;7:320-335.
104. Bagley J, Bracy J, Tian C, Kang E-S, Iacomini J: Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci 2002;7:1333-1337.
105. Moore DJ, Markmann JF, Deng S: Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transpl Int 2006;19:435-445.
106. Bracy JL, Sachs DH, Iacomini J: Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science 1998;281:1845-1847.
107. Madsen JC, Superina RA, Wood KJ, Morris PJ: Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 1988;332:161-164.
108. Bagley J, Tian C, Sachs DH, Iacomini J: Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood 2002;99:4394-4399.
109. Kang E-S, Iacomini J: Induction of central deletional T cell tolerance by gene therapy. J Immunol 2002;169:1930-1935.
110. Forman D, Kang E-S, Tian C, Paez-Cortez J, Iacomini J: Induction of alloreactive CD4 T cell tolerance in molecular chimeras: a possible role for regulatory T cells. J Immunol 2006;176:3410-3416.
111. Ohdan H, Sykes M: B cell tolerance to xenoantigens. Xenotransplantation 2003;10:98-106.
112. Yang YG, deGoma E, Ohdan H, Bracy JL, Xu Y, Iacomini J, Thall AD, Sykes M: Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism. J Exp Med 1998;187:1335-1342.
113. Ohdan H, Yang Y-G, Shimizu A, Swenson KG, Sykes M: Mixed chimerism induced without lethal conditioning prevents T cell-and anti-Galα1,3Gal- mediated graft rejection. J Clin Invest 1999;104:281-290.
114. Ohdan H, Yong-Guang Y, Swenson KG, Kitamura H, Sykes M: T cell and B cell tolerance to Gal α1,3Gal-expressing heart xenografts is achieved in α1,3-galactosyltransferase-deficient mice by non-myeloablative induction of mixed chimerism. Transplantation 2001;71:1532-1542.
115. Kawahara T, Shimizu I, Ohdan H, Zhao G, Sykes M: Differing Mechanisms of Early and Late B Cell Hyporesponsiveness Induced by Mixed Chimerism. Am J Transplant 2005;5:2821-2829.
116. Sykes M, Shimizu I, Kawahara T: Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance. Transplantation 2005;79:28-29.
117. Bracy JL, Iacomini J: Induction of B-cell tolerance by retroviral gene therapy. Blood 2000;96:3008-3015.
118. Buhler L, Awwad M, Treter S, Chang Q, Basker M, Alwayn IP, Teranishi K, Ericsson T, Moran K, Harper D, et al: Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regiment and CD154 blockade. Transplantation 2002;73:12-22.
119. Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig KW, Iacomini J: Prevention of type 1 diabetes by gene therapy. J Clin Invest 2004;114:969-978.
120. Bemelman F, Yong S-L, Tissingh R, Schellekens P, ten Berge I: Suppression extends to major histocompatibility antigens linked to tolerizing minor histocompatibility antigens, but not the other way round. Transpl Int 2005;18:423-428.
121. Sonntag KC, Emery DW, Yasumoto A, Haller G, Germana S, Sablinski T, Shimizu A, Yamada K, Shimada H, Arn S, et al: Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest 2001;107:65-71.